PTO/SB/08B (01-08)

Approved for use through 03/31/2008. OMB 0651-0031

Un	der the Paperwork Rec	luction A	ct of 1995, no persons a	re required to respond to a collection	of information unless it contains a valid OMB control number.	
Substitute for form 1449/PTO				Complete if Known		
ĺ				Application Number	10/520,152	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	January 3, 2005	
				First Named Inventor	Wessling	
				Art Unit	1611	
				Examiner Name	GHALI, Isis	
Sheet	1	of	1	Attorney Docket Number	512100-2044	

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		JEAL, W. and BENFIELD P.; Transdermal fentanyl. A review of its pharmacological properties; Drugs, Jan. 1997; 53 (1): 109-38; Auckland, New Zealand.				
		WARD, ME et al.; Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system; Clin. Pharmacol Ther.; Dec 1997; 62 (6): 596-609; Sydney, Aust.				
		MYSTAKIDOU, K. et al.; From codeine to transdermal fentanyl for cancer pain control; Anticancer Research; May-Jun 2001; 21 (3C): 2225-30; Athens, Greece.				

Signature Considered Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through cliation if not in conformance and not considered, which form with next communication to applicant.

Date

Examiner

considered. Include copy of the form win nex communication to appetant to place a check mark here! English Intropages Translation is advantaged to the control of the contr